Triple Negative Breast Cancer
Clinical research in early stage triple negative breast cancer focuses on neoadjuvant immunotherapy and chemotherapy, with interest in treatment strategies for stage I-II disease and the role of immune checkpoint inhibition in primary breast tumours.
- Nivolumab and immune-chemotherapy combinations
- Neoadjuvant treatment in primary breast cancer
- Stage I-II triple negative breast cancer
The sponsor’s work in this area is centred on breast cancer treatment innovation through immune-based approaches for aggressive early disease.
Breast Cancer Prevention
Preventive research addresses the reduction of breast cancer risk in women with germline BRCA1 mutation, with attention to both invasive breast cancer and ductal carcinoma in situ.
- BRCA1-associated cancer prevention
- Risk reduction for invasive disease
- Prevention of ductal carcinoma in situ
This area reflects a strong therapeutic focus on hereditary breast cancer and interventions aimed at lowering future cancer incidence in genetically predisposed women.
Hereditary Cancer Risk
Research activity extends to the clinical implications of BRCA1 germline mutation, with emphasis on women at elevated inherited risk and the prevention of malignancy before onset of disease.
- Inherited susceptibility to breast cancer
- Genetic risk management
- Women carrying BRCA1 mutations
The sponsor is active in the field of genetic oncology, particularly where inherited mutation status shapes preventive care options.
Oncology Immunotherapy and Bone-Targeted Prevention
The portfolio includes interest in immunotherapy for breast malignancy and in denosumab as a preventive strategy within a high-risk breast cancer setting, linking cancer immunology with bone-targeted therapy.
- Denosumab in cancer prevention
- Immune-based breast cancer treatment
- High-risk oncology prevention
These topics place the sponsor within clinical research on therapeutic prevention and immune-modulating approaches for breast cancer.
